Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Brief: AbCellera Q2 Revenue USD 17.1 Million Vs. IBES Estimate USD 6.12 Million

Overview

AbCellera Q2 2025 revenue of $17.1 mln beats analyst expectations, per LSEG data

Net loss narrows to $34.7 mln from $36.9 mln in Q2 2024

Result Drivers

REVENUE GROWTH - Revenue increased to $17.1 mln, driven by higher licensing revenue

STRONG LIQUIDITY - Over $750 mln in available liquidity supports ongoing strategy

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 RevenueBeat$17.10 mln$6.12 mln (6 Analysts)
Q2 Net Income-$34.70 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the biotechnology & medical research peer group is "buy" Wall Street's median 12-month price target for Abcellera Biologics Inc is $9.00, about 54.2% above its August 6 closing price of $4.12 Press Release: ID:nBw4Sf3WTa (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AbCellera Biologics

See all news